MA53131A - Composition immunogène pour la paratuberculose - Google Patents

Composition immunogène pour la paratuberculose

Info

Publication number
MA53131A
MA53131A MA053131A MA53131A MA53131A MA 53131 A MA53131 A MA 53131A MA 053131 A MA053131 A MA 053131A MA 53131 A MA53131 A MA 53131A MA 53131 A MA53131 A MA 53131A
Authority
MA
Morocco
Prior art keywords
paratuberculosis
immunogenic composition
immunogenic
composition
Prior art date
Application number
MA053131A
Other languages
English (en)
Inventor
John Hermon-Taylor
Original Assignee
Hav Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hav Vaccines Ltd filed Critical Hav Vaccines Ltd
Publication of MA53131A publication Critical patent/MA53131A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA053131A 2018-07-11 2019-07-10 Composition immunogène pour la paratuberculose MA53131A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1811382.9A GB201811382D0 (en) 2018-07-11 2018-07-11 Vaccine

Publications (1)

Publication Number Publication Date
MA53131A true MA53131A (fr) 2021-05-19

Family

ID=63273113

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053131A MA53131A (fr) 2018-07-11 2019-07-10 Composition immunogène pour la paratuberculose

Country Status (14)

Country Link
US (2) US12186382B2 (fr)
EP (1) EP3820507A1 (fr)
JP (2) JP2021524485A (fr)
KR (1) KR20210033490A (fr)
CN (1) CN113329765A (fr)
AU (1) AU2019301899A1 (fr)
BR (1) BR112021000312A2 (fr)
CA (1) CA3105763A1 (fr)
GB (1) GB201811382D0 (fr)
IL (1) IL280070B2 (fr)
MA (1) MA53131A (fr)
MX (1) MX2020013924A (fr)
SG (1) SG11202100120TA (fr)
WO (1) WO2020012177A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
WO2026041756A1 (fr) 2024-08-21 2026-02-26 Hav Vaccines Limited Traitement de la maladie de crohn au moyen d'un agent contre mycobacterium avium ssp. paratuberculosis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5225324A (en) 1987-04-24 1993-07-06 Bioscience International, Inc. Diagnostics for mycobacteria in public health, medical, and veterinary practice
GB8709803D0 (en) 1987-04-24 1987-05-28 Mcfadden J J Treatment of crohn's disease &c
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
CA2131620A1 (fr) 1992-03-20 1993-09-30 Louis C. Smith Systeme de transport de l'adn et mode d'emploi
DK0636028T3 (da) 1992-04-03 2004-07-12 Univ California Selvorganiserende polynucleotidleveringssystem omfattende et amfipatisk kationisk peptid
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
GB9526178D0 (en) 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
DK1913020T3 (da) 2005-08-09 2010-08-09 Hav Vaccines Ltd Immunogene konstrukter
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
IN2012DN00446A (fr) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
US9109249B2 (en) 2011-05-19 2015-08-18 University Of Central Florida Research Foundation, Inc. Microbe detection via hybridizing magnetic relaxation nanosensors
WO2014016737A1 (fr) 2012-07-24 2014-01-30 Pfizer Inc. Nouveaux anticorps monoclonaux de poulet dirigés contre la protéine tau phosphorylée humaine et leurs utilisations
AU2014209809A1 (en) * 2013-01-28 2015-08-06 Danmarks Tekniske Universitet A single or multistage Mycobacterium avium subsp. paratuberculosis subunit vaccine
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic

Also Published As

Publication number Publication date
KR20210033490A (ko) 2021-03-26
JP2021524485A (ja) 2021-09-13
CA3105763A1 (fr) 2020-01-16
US12186382B2 (en) 2025-01-07
EP3820507A1 (fr) 2021-05-19
IL280070B2 (en) 2024-04-01
CN113329765A (zh) 2021-08-31
JP2024153666A (ja) 2024-10-29
IL280070A (en) 2021-03-01
AU2019301899A1 (en) 2021-01-14
GB201811382D0 (en) 2018-08-29
BR112021000312A2 (pt) 2021-04-13
IL280070B1 (en) 2023-12-01
US20210338791A1 (en) 2021-11-04
WO2020012177A1 (fr) 2020-01-16
US20250152691A1 (en) 2025-05-15
SG11202100120TA (en) 2021-02-25
MX2020013924A (es) 2021-03-02

Similar Documents

Publication Publication Date Title
EP3630189A4 (fr) Lieurs pour conjugués anticorps-médicament
EP3739016A4 (fr) Composition de polissage
EP3423044A4 (fr) Nanovaccin activant sting pour l'immunothérapie
EP3356612A4 (fr) Détail facilité pour membranes d'imperméabilisation pré-appliquées
EP3630078A4 (fr) Agents pour chimio-embolisation
EP3853332C0 (fr) Composition
EP3882323A4 (fr) Composition
DK3840596T3 (da) Sammensætning
EP3560902A4 (fr) Composition pour marbre artificiel
EP3375432A4 (fr) Composition pour la cavité buccale
EP3897866C0 (fr) Composition antimicrobienne
DK3371126T3 (da) Manipuleret hybrid cementbaseret sammensætning med øget modstandsdygtighed over for befugtning
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
EP3725860A4 (fr) Composition pour encapsulation
IL282753A (en) Immunogenic composition
EP3394006A4 (fr) Accélérateur pour composition hydraulique
EP3778823A4 (fr) Composition de polissage
EP3790652A4 (fr) Composition de mouillage améliorée
EP3818102A4 (fr) Nouvelles compositions pour amérisants
MA53131A (fr) Composition immunogène pour la paratuberculose
EP3684830A4 (fr) Nouvelles compositions pour applications de polyuréthane
EP3338644A4 (fr) Capuchon pour découpe d'échantillons
DK3623432T3 (da) Sammensætning
EP3623430C0 (fr) Composition
EP3808785A4 (fr) Composition